GlassScriptPhysician profile
Elizabeth C Smith
NPI 1528226750
$4,934.08
in general payments reported to CMS, 2019-2025
36 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $28.50 · 2021: $181 · 2022: $652 · 2023: $1,118 · 2024: $997 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,956 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,955.87 |
| Education | $263.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $675.66 | 2022-2025 | Tremfya |
| Abbvie INC. | $547.64 | 2022-2025 | Skyrizi |
| Leo Pharma INC. | $518.30 | 2022-2025 | Adbry, Anzupgo |
| Merz North America, INC. | $465.24 | 2019-2023 | |
| Galderma Laboratories, L.P. | $399.21 | 2019-2025 | Aklief, Nemluvio |
| Pfizer INC. | $345.64 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $306.54 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $187.04 | 2023-2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $184.63 | 2019-2024 | Absorica Ld, Winlevi |
| Amgen INC. | $143.22 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $132.52 | 2023-2024 | Sotyktu |
| Lilly USA, LLC | $90.87 | 2020-2025 | Ebglyss |
| Genzyme Corporation | $85.77 | 2022-2023 | |
| Krystal Biotech INC | $73.93 | 2025 | Vyjuvek |
| Encore Dermatology INC. | $73.05 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $67.05 | 2024 | Ycanth |
| Journey Medical Corporation | $66.78 | 2022-2025 | |
| Acelrx Pharmaceuticals, INC. | $60.34 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.85 | 2024-2025 | Cabtreo, Jublia |
| Incyte Corporation | $47.84 | 2025 | Opzelura |
| Ucb, INC. | $47.43 | 2025 | Bimzelx |
| Merck Sharp & Dohme LLC | $33.80 | 2019 | |
| Genentech USA, INC. | $33.54 | 2025 | Xolair |
| Organon LLC | $32.61 | 2025 | Vtama |
| Fresenius Kabi USA, LLC | $31.40 | 2023 | |
| Vyne Pharmaceuticals INC. | $29.27 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $26.68 | 2025 | Libtayo |
| Organogenesis INC. | $26.53 | 2024 | Puraply Wound Matrix |
| Botanix Sb INC | $26.22 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $22.28 | 2019 | |
| Biofrontera INC. | $21.74 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Medtronic, INC. | $17.67 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.26 | 2024 | Spevigo |
| Molnlycke Health Care US, LLC | $15.92 | 2019 | |
| Prugen, INC. Pharmaceuticals | $13.38 | 2019 | |
| Allergan, INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.